載入...
预测贝伐珠单抗抗肿瘤治疗效果的生物学标记物
Bevacizumab, the monoclonal antibody of vascular endothelial growth factor (VEGF) has been applied to the therapy of several neoplasms, but an appropriate biomarker to predict the efficacy has not been found. Tose markers can originate from peripheral circulation, tumor tissue and genes. Some resear...
Na minha lista:
| 發表在: | Zhongguo Fei Ai Za Zhi |
|---|---|
| 格式: | Artigo |
| 語言: | Inglês |
| 出版: |
中国肺癌杂志编辑部
2011
|
| 主題: | |
| 在線閱讀: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6000279/ https://ncbi.nlm.nih.gov/pubmed/21762631 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3779/j.issn.1009-3419.2011.07.08 |
| 標簽: |
添加標簽
沒有標簽, 成為第一個標記此記錄!
|